SPDR S&P Biotech ETF Rating $128.67 -4.75 (-3.56%) As of 06/5/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock SPDR S&P Biotech ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.76Holdings in XBI have an aggregate rating of Moderate Buy based on 393 analyst ratings issued in the past year covering 25 companies (34.2% of the portfolio).XBI Aggregate Price Target$128.67High Prediction$128.67Average Prediction$128.67Low Prediction$128.67Holdings in XBI have an aggregate price target of $128.67 and a range of $128.67 to $128.67 covering 25 companies (34.2% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy20 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XBI Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.78%RVMDRevolution Medicines$149.23-4.1%2.1106 of 5 stars3.00$123.72 -17.1%22News CoverageAnalyst ForecastAnalyst Revision1.75%TVTXTravere Therapeutics$45.81-0.8%1.8184 of 5 stars2.69$48.92 6.8%13News CoverageAnalyst Forecast1.62%TGTXTG Therapeutics$40.16-1.0%3.6556 of 5 stars2.71$52.50 30.7%71.55%ALKSAlkermes$42.80-1.3%2.2001 of 5 stars2.76$45.40 6.1%171.51%ARWRArrowhead Pharmaceuticals$73.09-2.8%2.8453 of 5 stars2.75$87.80 20.1%121.51%TWSTTwist Bioscience$69.22-6.4%1.278 of 5 stars2.75$58.00 -16.2%8News CoverageGap Down1.41%CYTKCytokinetics$71.48-1.1%2.8229 of 5 stars2.86$99.30 38.9%221.41%NBIXNeurocrine Biosciences$163.88-2.1%4.3926 of 5 stars2.87$187.52 14.4%23Analyst ForecastInsider Trade1.40%MDGLMadrigal Pharmaceuticals$486.98-1.2%3.0629 of 5 stars2.78$687.00 41.1%181.40%EXELExelixis$52.70+0.4%2.9444 of 5 stars2.39$47.35 -10.1%23Insider Trade1.39%CELCCelcuity$88.28-4.5%3.0124 of 5 stars2.83$152.09 72.3%12Trending NewsAnalyst ForecastAnalyst Revision1.37%KRYSKrystal Biotech$301.00-2.2%3.3519 of 5 stars2.83$324.11 7.7%12News CoverageInsider Trade1.35%PRAXPraxis Precision Medicines$254.00-4.1%2.8593 of 5 stars2.95$572.72 125.5%20News CoverageAnalyst ForecastAnalyst Revision1.30%SRRKScholar Rock$44.30-2.3%3.3427 of 5 stars3.12$56.00 26.4%17Positive News1.28%BEAMBeam Therapeutics$29.40-10.5%2.1231 of 5 stars2.71$46.83 59.3%141.27%APGEApogee Therapeutics$86.92-4.4%3.1859 of 5 stars2.74$113.63 30.7%19Insider Trade1.25%MIRMMirum Pharmaceuticals$93.48+1.1%3.3968 of 5 stars2.93$137.64 47.2%15Positive NewsAnalyst ForecastInsider Trade1.22%PTCTPTC Therapeutics$70.97+0.5%3.6976 of 5 stars2.64$89.00 25.4%14Positive News1.22%UTHRUnited Therapeutics$549.87+0.4%4.3865 of 5 stars2.85$619.42 12.6%13Insider Trade1.21%VCYTVeracyte$48.73-2.4%1.6862 of 5 stars2.56$47.57 -2.4%9Trending NewsAnalyst ForecastInsider Trade1.21%NTRANatera$215.31-3.1%4.2132 of 5 stars2.81$256.12 19.0%21Analyst ForecastInsider Trade1.21%IMVTImmunovant$31.11-4.8%2.6303 of 5 stars2.45$37.33 20.0%111.20%INCYIncyte$102.38+1.1%3.9553 of 5 stars2.36$104.00 1.6%22Analyst Forecast1.20%HALOHalozyme Therapeutics$71.53-0.1%4.5544 of 5 stars2.54$81.60 14.1%13Trending NewsAnalyst ForecastInsider TradeAnalyst Revision1.20%PTGXProtagonist Therapeutics$97.38-5.3%2.423 of 5 stars2.88$115.21 18.3%16Positive News This page (NYSEARCA:XBI) was last updated on 6/7/2026 by MarketBeat.com Staff. From Our Partners$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XBI Stock Alerts